Welcome to our dedicated page for Medpace Holdings SEC filings (Ticker: MEDP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Medpace Holdings, Inc. (Nasdaq: MEDP), a scientifically driven, global, full-service clinical contract research organization (CRO). Through these filings, investors can review the company’s official financial statements, risk disclosures, material agreements and other regulatory information that frame analysis of MEDP stock.
Medpace’s SEC reporting includes annual reports on Form 10-K, which contain audited financial statements, management’s discussion and analysis, and a detailed “Risk Factors” section describing uncertainties such as contract loss, backlog conversion, pricing pressure, international operations, regulatory compliance, and information systems risks. Quarterly reports on Form 10-Q provide interim financial updates and additional context on operating performance in the clinical research and development services business.
The company also files current reports on Form 8-K to disclose specific events. For example, Medpace has used Form 8-K to furnish earnings press releases under Item 2.02 and to describe amendments to its unsecured credit facility under Item 1.01, including changes to the aggregate principal amount available under its line of credit. These filings give detail on financing arrangements and other material developments beyond the headline numbers in press releases.
On Stock Titan, Medpace filings are paired with AI-powered summaries that highlight key points from lengthy documents, such as major changes in revenue and profitability, updates to guidance, or notable shifts in risk disclosures. Users can quickly scan 10-K and 10-Q reports, as well as 8-K items, while retaining the option to open the full SEC documents for deeper review. This page also surfaces information relevant to tracking management decisions, capital structure, and other regulatory matters that influence Medpace’s long-term profile as a global CRO.
Medpace Holdings, Inc. (MEDP) CEO August J. Troendle, who is also a director and 10% owner, reported open-market sales of Medpace common stock. On 11/24/2025, he sold 59,025 shares at a weighted average price of $607.78 per share, and on 11/25/2025 he sold 42,392 shares at a weighted average price of $615.52 per share. After these transactions, he directly beneficially owns 774,602 shares and indirectly beneficially owns 4,733,019 shares through Medpace Investors, LLC, over which he has voting and investment control and for which he disclaims beneficial ownership beyond his economic interest.
Medpace Holdings, Inc. executive reports stock sale
A Medpace Holdings, Inc. executive vice president of operations filed a Form 4 reporting the sale of 20,000 shares of Medpace common stock on 11/24/2025. The shares were sold at a weighted average price of $609.15 per share, through multiple trades within a price range of $607.59 to $610.92, executed under a pre-placed limit order during an open trading window. Following this transaction, the reporting person directly holds 27,500 shares of Medpace common stock.
Medpace Holdings, Inc. (MEDP)11/21/2025, he exercised an employee stock option for 3,000 shares of common stock at an exercise price of $166.73 per share, increasing his holdings, then sold 3,000 shares of common stock in a market transaction coded as a sale. The reported sale price is a weighted average of $590.35 per share, based on multiple trades between $590.00 and $590.72 placed via a limit order during an open trading window.
On the same date, Brady also gifted 170 shares of common stock to a donor-advised fund. After these transactions, he directly beneficially owned 5,830 shares of Medpace common stock. The employee stock option for 3,000 shares, which had vested in full on October 27, 2025, was fully exercised and no longer outstanding following the reported activity.
Medpace Holdings, Inc. (MEDP) CEO, director and 10% owner August J. Troendle reported open‑market sales of Medpace common stock. On 11/20/2025 he sold 6,830 shares at a weighted average price of $598.49, with individual trades ranging from $590.00 to $604.23. On 11/21/2025 he sold 21,858 shares at a weighted average price of $592.18, with trades ranging from $590.00 to $595.58. The transactions were effected under a limit order placed during an open window period. Following these sales, he directly beneficially owns 833,627 shares and indirectly beneficially owns 4,733,019 shares through Medpace Investors, LLC, where he has sole voting and investment control and may be deemed to beneficially own those securities to the extent of his pecuniary interest.
Medpace Holdings, Inc. (MEDP) CEO, director and 10% owner August J. Troendle reported selling common stock in two transactions in November 2025. On November 18, 2025, he sold 7,191 shares at a weighted average price of $590.84, leaving 886,177 shares owned directly. On November 19, 2025, he sold an additional 23,862 shares at a weighted average price of $592.07, leaving 862,315 shares owned directly.
The filing notes these trades were executed under a limit order during an open trading window and that prices reflect multiple trades within disclosed ranges. Troendle also reports indirect beneficial ownership of 4,733,019 shares held by Medpace Investors, LLC, where he is the sole manager and controlling unitholder, while formally disclaiming beneficial ownership beyond his economic interest.
Medpace Holdings, Inc. (MEDP) director Robert O. Kraft reported an option exercise and share sale. On 11/14/2025, he exercised a stock option for 6,472 shares of common stock at an exercise price of $54.99 per share, increasing his directly held shares. On the same day, he sold 6,472 shares of common stock at a weighted average price of $591.85 per share, in multiple trades priced between $588.98 and $596.543. After these transactions, he reported owning 833 shares of Medpace common stock directly and no remaining derivative securities from this option.
Medpace Holdings (MEDP) CEO and 10% owner August J. Troendle reported open‑market stock sales. On 11/14/2025, he sold 14,747 shares of Medpace common stock at a weighted average price of $595.26 per share, followed by a sale of 6,047 shares on 11/17/2025 at a weighted average price of $591.00 per share. The sales were executed pursuant to a limit order placed during an open trading window. After these transactions, he beneficially owns 893,368 shares directly and 4,733,019 shares indirectly through Medpace Investors, LLC, where he is the sole manager and controlling unit holder.
Medpace Holdings (MEDP) insider activity: August J. Troendle, CEO, director and 10% owner, reported open‑market sales of common stock executed via a limit order during an open window period. On 11/12/2025, he sold 5,312 shares at a weighted average price of $603.23. On 11/13/2025, he sold 5,128 shares at a weighted average price of $601.37.
After these transactions, he directly owned 914,162 shares. He also reports indirect beneficial ownership of 4,733,019 shares through Medpace Investors, LLC, over which he has voting and investment control, while disclaiming beneficial ownership beyond his pecuniary interest.
Medpace Holdings, Inc. (MEDP) disclosed an insider sale by an executive officer. Exec. VP, Operations Susan E. Burwig sold 18,000 shares of common stock on 11/11/2025 at a price of $605 per share (Transaction Code S). Following the sale, she beneficially owns 47,500 shares, held directly.
The filing notes the trade was executed via a limit order during an open window period.
Medpace Holdings (MEDP) insider transaction: President Jesse J. Geiger reported selling 21,503 shares of common stock on 11/05/2025. The weighted average sale price was $595.66 per share, with individual trades executed between $588.64 and $599.86. Following these transactions, he reported beneficial ownership of 15,000 shares, held directly.
The filing notes the sales were made under a Rule 10b5-1 trading plan adopted on August 6, 2025.
FAQ
What is the current stock price of Medpace Holdings (MEDP)?
What is the market cap of Medpace Holdings (MEDP)?
